lithium carbonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4207	554-13-2

Description:

Molecule	Description
Synonyms: lithium carbonate carbonic acid, dilithium salt dilithium carbonate	A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems. Molecular weight: 73.89 Formula: CLi2O3 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 63.19 ALOGS: ROTB: None

Molecule

Description

Synonyms:

lithium carbonate
carbonic acid, dilithium salt
dilithium carbonate

A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.

Molecular weight: 73.89
Formula: CLi2O3
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 63.19
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
24	mmol	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	95 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	13 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	116.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Showing 1 to 4 of 4 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
April 6, 1970	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxicity to various agents	1461.12	13.06	1368	50629	245882	63191143
Tremor	809.75	13.06	748	51249	131491	63305534
Antipsychotic drug level increased	799.42	13.06	233	51764	3202	63433823
Neuroleptic malignant syndrome	690.69	13.06	287	51710	11769	63425256
Nephrogenic diabetes insipidus	659.90	13.06	154	51843	805	63436220
Drug interaction	636.63	13.06	857	51140	228274	63208751
Mania	549.40	13.06	246	51751	12121	63424904
Extrapyramidal disorder	516.99	13.06	241	51756	13043	63423982
Sopor	362.48	13.06	226	51771	21938	63415087
Agitation	345.68	13.06	328	51669	59429	63377596

Showing 1 to 10 of 468 entries

Previous1 2 3 4 5…47Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxicity to various agents	886.18	13.80	1111	38677	199251	34717892
Neuroleptic malignant syndrome	598.85	13.80	326	39462	17608	34899535
Antipsychotic drug level increased	572.09	13.80	201	39587	3664	34913479
Tremor	536.14	13.80	560	39228	82027	34835116
Mania	496.63	13.80	234	39554	9277	34907866
Nephrogenic diabetes insipidus	398.49	13.80	118	39670	1203	34915940
Akathisia	370.25	13.80	182	39606	7927	34909216
Suicide attempt	354.65	13.80	319	39469	38797	34878346
Obsessive-compulsive disorder	331.32	13.80	150	39638	5414	34911729
Antipsychotic drug level below therapeutic	311.32	13.80	115	39673	2432	34914711

Showing 1 to 10 of 330 entries

Previous1 2 3 4 5…33Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxicity to various agents	2048.04	13.20	2267	75056	419273	79247792
Tremor	1270.28	13.20	1158	76165	168925	79498140
Antipsychotic drug level increased	1268.01	13.20	392	76931	5565	79661500
Neuroleptic malignant syndrome	1169.29	13.20	559	76764	27000	79640065
Nephrogenic diabetes insipidus	955.84	13.20	251	77072	1883	79665182
Mania	806.82	13.20	381	76942	17879	79649186
Drug interaction	798.47	13.20	1435	75888	413748	79253317
Extrapyramidal disorder	760.10	13.20	392	76931	22287	79644778
Agitation	466.24	13.20	528	76795	99187	79567878
Antipsychotic drug level above therapeutic	460.00	13.20	141	77182	1939	79665126

Showing 1 to 10 of 562 entries

Previous1 2 3 4 5…57Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N05AN01	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Lithium
CHEBI has role	CHEBI:35477	antimanic drugs
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D018692	Antimanic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents

Showing 1 to 9 of 9 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Bipolar disorder	indication	13746004	DOID:3312
Pain	indication	22253000
Rheumatoid arthritis	indication	69896004	DOID:7148
Bipolar disorder in remission	indication	85248005
Bipolar affective disorder, current episode manic	indication	191618007
Headache disorder	indication	230461009
Dysmenorrhea	indication	266599000
Fever	indication	386661006
Osteoarthritis	indication	396275006
Juvenile rheumatoid arthritis	indication	410795001

Showing 1 to 10 of 29 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glycogen synthase kinase-3	Kinase	P49840 P49841	GSK3A_HUMAN GSK3B_HUMAN	INHIBITOR				CHEMBL	CHEMBL
Inositol-1(or 4)-monophosphatase 1	Enzyme	P29218	IMPA1_HUMAN	INHIBITOR				CHEMBL	CHEMBL

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
001532	NDDF
001533	NDDF
11125	PUBCHEM_CID
16977003	SNOMEDCT_US
1990	MMSL
2BMD2GNA4V	UNII
3028194	PUBCHEM_CID
321719003	SNOMEDCT_US
387095003	SNOMEDCT_US
4018007	VUID

Showing 1 to 10 of 29 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lithium Carbonate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0020	TABLET, EXTENDED RELEASE	450 mg	ORAL	ANDA	16 sections
Lithium Carbonate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0020	TABLET, EXTENDED RELEASE	450 mg	ORAL	ANDA	16 sections
Lithium Carbonate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0020	TABLET, EXTENDED RELEASE	450 mg	ORAL	ANDA	16 sections
Lithium Carbonate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0021	TABLET, EXTENDED RELEASE	300 mg	ORAL	ANDA	13 sections
Lithium Carbonate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0021	TABLET, EXTENDED RELEASE	300 mg	ORAL	ANDA	13 sections
Lithium Carbonate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0021	TABLET, EXTENDED RELEASE	300 mg	ORAL	ANDA	13 sections
Lithium Carbonate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-2526	CAPSULE, GELATIN COATED	150 mg	ORAL	NDA	26 sections
Lithium Carbonate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-2526	CAPSULE, GELATIN COATED	150 mg	ORAL	NDA	26 sections
Lithium Carbonate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-2526	CAPSULE, GELATIN COATED	150 mg	ORAL	NDA	26 sections
Lithium Carbonate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-2527	CAPSULE, GELATIN COATED	300 mg	ORAL	NDA	26 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next